25,99 €
inkl. MwSt.
Versandfertig in 6-10 Tagen
13 °P sammeln
Andere Kunden interessierten sich auch für
![Miltefosine pour le traitement de la leishmaniose tégumentaire américaine]( "Miltefosine pour le traitement de la leishmaniose tégumentaire américaine")
Miltefosine pour le traitement de la leishmaniose tégumentaire américaine25,99 €![An experimental approach in the treatment of acute intestinal obstruction]( "An experimental approach in the treatment of acute intestinal obstruction")
An experimental approach in the treatment of acute intestinal obstruction31,99 €![Modern approach to the treatment of patients with CHD]( "Modern approach to the treatment of patients with CHD")
Modern approach to the treatment of patients with CHD37,99 €![Biology of Visceral Leishmaniasis]( "Biology of Visceral Leishmaniasis")
Biology of Visceral Leishmaniasis46,99 €![The Titling of Remaining Quilombo Lands]( "The Titling of Remaining Quilombo Lands")
The Titling of Remaining Quilombo Lands34,99 €![The development of shale gas resources in Brazil]( "The development of shale gas resources in Brazil")
The development of shale gas resources in Brazil27,99 €![Assessing the health status of women who have undergone hysterectomy]( "Assessing the health status of women who have undergone hysterectomy")
Assessing the health status of women who have undergone hysterectomy34,99 €
American Tegumentary Leishmaniasis (ATL) is a major public health problem, especially in developing countries. There have been few pharmacological advances for ATL. Pentavalent antimonials require monitoring because they are cardiotoxic, hepatotoxic and nephrotoxic. One of the alternatives is miltefosine, an oral drug that has shown good effectiveness in some Leishmania species. Objective: To review the evidence for the efficacy and safety of miltefosine in monotherapy or in combination. Method: Preparation of a Technical-Scientific Opinion. Results: 6 studies were selected. The clinical trials showed cure rates at six months ranging from 58.6 to 87.9% in the miltefosine treatment group and from 53.3 to 93.7% in the meglumine group. Calculation of the RR of the studies showed a small association between miltefosine and the six-month cure rate (RR=1.02). Only one study showed a cure rate at three months of 67.6% and 78.3% in the miltefosine and meglumine groups, respectively. As for safety, miltefosine had less serious adverse events compared to meglumine, the most frequent being gastrointestinal symptoms.